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Abstract: Bacillus subtilis is a soil dwelling organism which uses alternative extracytoplasmic 
function (ECF) sigma factors that respond to environmental stressors encountered by a cell.  
Upon encountering a signal, ECF sigma factors are activated and bind RNAP to initiate 
transcription of genes that confer resistance to stressors that threaten cellular integrity [5]. One 
such factor, sigmaV (V), is required by B. subtilis for resistance to lysozyme. In the absence of 
lysozyme, V is inhibited by the anti-sigma factor, RsiV, which is a transmembrane protein that 
has an extracellular lysozyme sensing domain. RsiV binds lysozyme, allowing for regulated 
intramembrane proteolysis (RIP) of the anti-sigma factor. The rate limiting step in degradation of 
RsiV is site-1 cleavage, which is performed by signal peptidase. Once RsiV is degraded it 
releases V, allowing it to bind RNAP and transcribe lysozyme resistance genes. We sought to 
understand how RsiV avoids signal peptidase cleavage in the absence of lysozyme. To 
investigate this, we fused various lengths of RsiV to GFP in order to identify portions of RsiV 
needed to shield it from signal peptidase cleavage in the absence of lysozyme. We also defined 
the transmembrane domain of RsiV using the substituted cysteine accessibility method (SCAM). 
These experiments contribute to our investigation of a putative amphipathic helix with protective 
properties from signal peptidase.  
 
Introduction: Sigma factors () are an essential component of RNA polymerase (RNAP). Some 
bacteria possess multiple σ factors that allow the cell to selectively transcribe genes whose 
products contribute to the cell’s survival. The RNAP core itself is unable to bind DNA and needs 
a  factor to make a holoenzyme. This holoenzyme is then able to locate the promoter region of 
a gene and begin synthesis of a few nucleotides before the  dissociates [3, 8, 13, 14].  In order 
to respond rapidly to an environment in constant flux bacteria employ multiple mechanisms, of 
which extracytoplasmic function sigma factors (ECF) are prominently used. Generally speaking, 
ECF activate the transcription of genes used to protect cellular envelope integrity [8, 14, 15]. The 
ECF factors are related to 70, which is the σ factor required for expression of housekeeping 
genes in bacteria [15]. 
 
In the absence of extracellular signal, the activity of some ECF are inhibited by an anti-sigma 
factor. In order to function, the ECF must be released from the anti-sigma factor. One 
mechanism for release is the regulated intramembrane proteolysis (RIP) of the anti-sigma factor 
[5, 10, 12]. This is a multi-step process that is initiated by a site-1 protease cleaving the anti-σ 
factor in the extracellular domain. This creates a substrate for the site-2 protease to cleave within 
the transmembrane domain of the anti-σ factor [10]. The remaining anti-sigma factor is then 
degraded by intracellular protease, thus freeing the ECF to bind RNAP [5, 10].  
 
One common cell envelope stressor is the hydrolytic enzyme, lysozyme, which is part of the 
innate immune system. In susceptible bacteria, lysozyme is capable of cleaving the -(1,4)-
glycosidic bond between N-acetylmuramic acid (MurNAc) and N-acetyl-glucosamine (GlcNAc) 
found in the peptidoglycan (PG) backbone [2, 9]. In several pathogenic organisms, lysozyme 
induces an ECF sigma factor, σV [1, 2, 5, 11]. The model organism, B. subtilis, also uses V to 
transcribe genes conferring resistance to lysozyme [4, 5, 8-10, 16]. Here, V is encoded in an 
operon with three other genes: rsiV (the σV anti-sigma factor), oatA (O-acetyltransferase) and 
yrhK (unknown function) [5, 9, 16]. In the absence of lysozyme, the activity of V is inhibited by 
the anti-sigma factor, RsiV.  
 
We previously demonstrated that RsiV acts as a receptor for lysozyme [6, 7]. RsiV is a single-
pass transmembrane protein that, upon lysozyme binding, becomes susceptible to RIP cleavage 
by site-1 and site-2 proteases (SipS or SipT and RasP, respectively). These events release V into 
the cytoplasm where it will bind RNAP and begin transcription of lysozyme resistance genes [5-
7]. One such gene induced in B. subtilis is oatA, whose protein product causes O-acetylation of 
MurNAc on the bacteria’s peptidoglycan [1, 4, 5, 9, 11]. In several organisms V also induces 
the dlt operon, causing D-alanylation of cell wall teichoic acids [1, 4, 11]. These pathways are 
thought to increase lysozyme resistance by blocking lysozyme access to the -(1,4)-glycosidic 
bonds or repelling it away due to a likeness in charge of the PG, respectively.  
 
It is generally thought that signal peptidases constitutively cleave their substrates. Yet RsiV is 
not immediately cleaved by signal peptidase in the absence of lysozyme. To better understand 
how RsiV protects itself from signal peptidase cleavage in the absence of lysozyme, we sought to 
define the extracellular region surrounding the RsiV signal peptidase cleavage sequence. By 
fusing various lengths of RsiV to GFP, we have identified a region sufficient for RsiV protection 
against signal peptidase. Since the signal peptidase motif is near the RsiV transmembrane (TM) 
domain, we also determined where the extracellular domain begins using the substituted cysteine 
accessibility method (SCAM). These experiments have contributed to our hypothesis that the 
extracellular region surrounding the signal peptidase cleavage site contains an amphipathic helix 
which conceals that sequence until RsiV binds lysozyme.  
 
Results  
RsiV amino acids 1-86 sufficiently protect against signal peptidase cleavage in the absence 
of lysozyme. As previously mentioned, RsiV is not immediately cleaved by signal peptidase in 
the absence of lysozyme. This suggests the presence of a protective region within the anti-σ 
factor. To help define these regions, we fused various lengths of RsiV to GFP. Constructs were 
made by PCR amplification using isolated B. subtilis PY79 DNA and a plasmid containing gfp as 
templates (see Materials and Methods). The resulting fragments were then assembled by Gibson 
assembly into pDR111, placing the rsiV-gfp fusion under the control of an IPTG inducible 
promoter and can integrate at the amyE loci of B. subtilis. Once confirmed by sequencing, the 
plasmids were introduced into B. subtilis ∆sigVrsiV::kan. The resulting strains were grown to 
mid-log phase in the presence of 1mM IPTG. The culture supernatant and cell pellets were 
collected for western blot analysis using anti-GFP antibody (1:10,000; anti-rabbit secondary 
antibody). We predicted GFP to be cleaved by signal peptidase and secreted into culture media if 
the RsiV-GFP fusion lacked sufficient protective features to avoid signal peptidase cleavage. 
Conversely, if the RsiV-GFP fusion has these protective qualities then we expect the protein to 
remain intact and associated with the cell pellet.  
 
We detected GFP in the culture supernatant and lysed cells when it was fused right after the 
RsiV signal peptidase motif (i.e. RsiV1-66; Figure 1). Similar results were seen when we fused 
GFP 10 amino acids downstream of said motif (i.e. RsiV1-76). However, when GFP was fused 20 
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and 30 amino acids downstream of RsiV signal peptidase cleavage site, no cleavage products 
were found (RsiV1-86 and RsiV1-96, respectively). These data suggest that amino acids 1-86 are 
sufficient for protecting RsiV from signal peptidase in the absence of lysozyme.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The RsiV extracellular domain begins around amino 
acid 60.        
We hypothesized that RsiV undergoes a conformational 
change upon binding to lysozyme exposes the signal 
peptidase cleavage motif, which is in close proximity to 
the TM domain. Defining the start of the RsiV 
extracellular domain would help aid in experimental 
planning and data interpretation. We used a substituted 
cysteine accessibility method (SCAM) to define the start 
of the extracellular domain of RsiV (wild-type RsiV lacks 
cysteine residues). Cysteine point mutations were 
introduced into the predicted transition region 
using site-directed PCR mutagenesis of B. 
subtilis PY79 with 6x histidine tag and an 
A66W point mutation for template (see 
Materials & Methods; Figure 2). For the 
reasons described above, Gibson assembly of 
Figure 1:  RsiV amino acids 1-86 are sufficient for protection from signal peptidase. RsiV-GFP fusion 
proteins from strains LTL423-LTL426. Unwashed, mid-log cell pellets and concentrated supernatants were 
used for western analysis. Expected bands: 1-66 RsiV-GFP ~36 kDa; 1-76 RsiV-GFP ~37 kDa; 1-86 RsiV-
GFP ~39 kDa; 1-96 RsiV-GFP ~40 kDa.  
Figure 2: RsiV amino residues point mutated to 
cysteine. Shown in green is V and RsiV is red. Our 
SCAM experiment incorporated 7 amino acids in which 
we thought the transition from TM to extracellular 
domains would occur.  
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each PCR mutagenesis product onto pDR111 was conducted, followed by vector transformation 
into B. subtilis PY79 ∆sigVrsiV::kan. These strains were then grown to mid-log phase before 
being labeled with Nα-(3-Maleimidylpropionyl)Biocytin (MPB), after which cells were lysed 
and RsiV purified using a nickel resin that bound to the 6x-histidine tag on RsiV.  
 
To ensure (1) each strain was able to express RsiV upon IPTG induction and (2) purified RsiV 
was isolated in similar amounts, we ran a western blot using an anti-RsiV antibody (1:10000 
dilution; anti-rabbit secondary antibody). This antibody was raised against amino acids 59-285 
and thus bound to each mutant RsiV regardless of the introduced cysteine or bound MPB (Figure 
3, top). We expected to see similar band intensities if strains expressed RsiV at similar levels, as 
seen in Figure 3. Therefore, the absence of fluorescence for some strains in the Streptavidin 
western blot cannot be explained by a decreased or inability to express the point-mutated RsiV 
(Figure 3, bottom).  
 
The MPB label does not cross membranes and, therefore, was expected to label only cysteines 
residing on the extracellular side of RsiV. To identify which cysteines were labeled we used to 
streptavidin-IRDYExxx which will bind to the biotinylated cysteine residues of RsiV with high 
specificity (IRDye 800CW; 1:10000 dilution). To make certain MPB labeled cysteines properly 
we used the following positive and negative controls, respectively: RsiV with a cysteine located 
far out in the extracellular domain and an RsiV containing no cysteine residues. We found that 
the no cysteine RsiV was not labeled while the positive control A167C did label with MPB 
(Figure 3, “A167C” and “No Cys”). 
 
We then compared the ability of residues 59-62 to label with MPB when they were mutated to 
cysteine. We found that residues 56-59 (i.e. L56C, V57C, N58C, and I59C) did not label, 
suggesting that these residues resided in within the transmembrane domain of RsiV. On the other 
hand, we did detect labeling with the N60C, P61C, and D62C mutant proteins which suggests 
that they were likely on the extracellular side of RsiV. Taken together these data indicate that the 
RsiV extracellular domain begins around amino acid N60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
Does RsiV have an amphipathic helix with protective properties?  
Previously, we aligned ~200 homologs of RsiV to identify highly conserved residues in the 
extracellular region surrounding the signal peptidase cleavage site (Figure 4). The alignment 
shows conserved hydrophobic and hydrophilic residues occurring at regular intervals. This 
suggests the presence of a putative amphipathic helix. Using a helical wheel projector, we 
observed the presence of a putative amphipathic helix (Figure 4, upper left). One experiment 
done to investigate this helix was a modified SCAM protocol. We have observed that a RsiVA66W 
protein is not cleaved by signal peptidase in the presence of lysozyme. Thus, we made cysteine 
point mutations into a RsiVA66W background in the proposed amphipathic helix region. The 
SCAM protocol was then used with RsiV in the presence and absence of lysozyme. This has 
shown us which residues are likely to reside in the cell’s membrane before and after RsiV binds 
to lysozyme. The data from this experiment is consistent with how we expect an amphipathic 
helix to be labeled by MPB (data not shown). 
 
We also think Figure 1 suggests that the putative amphipathic helix blocks signal peptidase 
cleavage in the absence of lysozyme. Based on this and our predicted location of the helix, we 
are making in-frame deletions of 67-76, 67-86, and 67-96 and 86-96. We plan to test these RsiV 
deletion mutants in a ß-galactosidase assay where V activity is measured in the absence of 
lysozyme. This assay will indirectly tell us if RsiV mutant is undergoing RIP (i.e. higher V 
activity correlates to RsiV being cleaved). We predict this experiment to further narrow down 
which portion of RsiV is necessary for protection from signal peptidase in the absence of 
lysozyme.  
 
In all, we propose a more refined model for how signal peptidase cleavage of RsiV controls –σV 
activation (Figure 5). We hypothesize that in the absence of lysozyme an amphipathic helix sits 
in the membrane, effectively masking the signal peptidase cleavage site. Once lysozyme binds to 
RsiV we predict that the helix moves out of the membrane allowing signal peptidase to cleave its 
substrate and initiate the RIP process and thus σV activation.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: RsiV transition from TM to extracellular domains. Westerns of a SCAM protocol using B. 
subtilis strains LTL279, LTL281, LTL301, LTL315, LTL325, LTL354, LTL369, LTL370, and LTL371 
(see Materials and Methods). MPB labeled RsiV was resuspended in 2x sample buffer + BME. Westerns 
were developed using LI-COR using IR channels 700 and 800. The RsiV protein is approximately 33 kD.  
 
Figure 4: Sequence alignment indicates a putative amphipathic helix. Sequencing of all gram positive 
organisms known to contain RsiV homologues in their genomes using Clustal Omega database. Highly 
conserved amino residues have a large font than those with less conservation. A wheel projection indicates 
a possible amphipathic helix in the extracellular region adjacent to the TM domain.  
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Figure 5: Revised model for regulated intramembrane proteolysis of RsiV. V is shown in green 
and is bound to RsiV in the absence of lysozyme (blue). Lysozyme is bound by the RsiV (red) 
extracellular sensing domain, shifting the amphipathic helix as a result. Signal peptidase (orange) 
now has access to its cleavage site on RsiV. Removal of the RsiV extracellular domain creates a 
proper substrate for site-2 protease, RasP (purple), to cleave in an intramembrane fashion.  
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Materials & Methods  
Strains:  
Strains Genotype Reference 
B. subtilis   
CDE1563 PY79 ΔsigVrsiV::kan  [5] 
LTL315 PY79 amyE:: Phs-6xhis -rsiVA167C, A66W(spec) ΔsigVrsiV::kan   
LTL279 PY79 amyE:: Phs-6xhis -rsiVA66W(spec) ΔsigVrsiV::kan  
LTL325 PY79 amyE:: Phs-6xhis -rsiVL56C, A66W(spec) ΔsigVrsiV::kan  
LTL369  PY79 amyE:: Phs-6xhis -rsiVV57C, A66W(spec) ΔsigVrsiV::kan  
LTL370 PY79 amyE:: Phs-6xhis -rsiVN58C, A66W(spec) ΔsigVrsiV::kan  
LTL354 PY79 amyE:: Phs-6xhis -rsiVI59C, A66W(spec) ΔsigVrsiV::kan  
LTL301 PY79 amyE:: Phs-6xhis -rsiVN60C, A66W(spec) ΔsigVrsiV::kan  
LTL371 PY79 amyE:: Phs-6xhis -rsiVP61C, A66W(spec) ΔsigVrsiV::kan  
LTL281 PY79 amyE:: Phs-6xhis -rsiVD62C, A66W(spec) ΔsigVrsiV::kan  
LTL423 PY79 amyE:: Phs-6xhis -rsiV1-66-GFP (spec) ΔsigVrsiV::kan  
LTL424 PY79 amyE:: Phs-6xhis-rsiV1-76-GFP (spec) ΔsigVrsiV::kan  
LTL425 PY79 amyE:: Phs-6xhis -rsiV1-86-GFP (spec) ΔsigVrsiV::kan  
LTL426 PY79 amyE:: Phs-6xhis-rsiV1-96-GFP (spec) ΔsigVrsiV::kan  
E. coli 
Omnimax 
  
CDEE2 F= proAB lacIq lacZ M15 Tn10(Tetr) ccdAB mcrA (mrr-hsdRMS-mcrBC) 80lacZ M15 
(lacZYA-argF) U169 endA1 recA1 supE44 thi-1 gyrA96 relA1 tonA panD  
Invitrogen 
Plasmids   
pDR111 amyE Phs specR ampR Phs [7] 
pLL169 pDR111 amyE Phs specRampR Phs-6xhis -rsiVA167C, A66W   
pLL158 pDR111 amyE Phs specRampR Phs-6xhis -rsiVA66W  
LTL323 pDR111 amyE Phs specRampR Phs-6xhis -rsiVL56C, A66W  
pLL187 pDR111 amyE Phs specRampR Phs-6xhis -rsiVV57C, A66W  
pLL194 pDR111 amyE Phs specRampR Phs-6xhis -rsiVN58C, A66W  
pLL180 pDR111 amyE Phs specRampR Phs-6xhis -rsiVI59C, A66W  
pLL161 pDR111 amyE Phs specRampR Phs-6xhis -rsiVN60C, A66W  
pLL188 pDR111 amyE Phs specRampR Phs-6xhis -rsiVP61C, A66W  
pLL160 pDR111 amyE Phs specRampR Phs-6xhis -rsiVD62C, A66W  
pLL197 pDR111 amyE Phs specRampR Phs-6xhis -rsiV1-66-GFP  
pLL194 pDR111 amyE Phs specRampR Phs-6xhis -rsiV1-76-GFP  
pLL195 pDR111 amyE Phs specRampR Phs-6xhis -rsiV1-86-GFP  
pLL196 pDR111 amyE Phs specRampR Phs-6xhis -rsiV1-96-GFP  
 
 
 
  
 
 
Primers: Table 2 (above). Note: all PCR amplification products (either cysteine mutated or 
RsiV-GFP PCR products) were cloned onto a pDR111 vector digested with HindIII-HF and 
SpHI. For fusion proteins – all PCR templates containing (1) pCM111 used CDEP3868 as the 3’ 
end primer or (2) B. subtilis PY79, a prototrophic derivative of B. subtilis strain 168, used 
CDEP3865 as the 5’ end primer [7].  
 
Q5TD PCR: Each reaction template was denatured at 94ºC for 30, then for 10 seconds. 
Annealing was at 60ºC for 20 seconds with -1ºC per cycle. Extension occurred at 68ºC for 1 min. 
This was then repeated for 10 cycles, starting from 10 seconds of 94ºC denaturing. Next, 
reactions were denatured at 94ºC for 10 seconds, then annealed at 50ºC for 20 seconds. 
Extension occurred at 68ºC for 30 seconds. These three steps were repeated for 25 cycles. 
Reactions were held at 69ºC for 5 minutes, followed by PCR termination.   
 
CDE Oligo 
Number 
Primer Sequence Primer Description 
Cysteine 
Mutations 
  
CDEP3195 ccgaattagcttgcatgctattttatcgaatataacgttctcc VP2 RsiV pDR111; end primer 
CDEP3629 gtgagcggataacaattaagct taaggaggctttcttaatg caccatcaccatcaccat Clone 6xhis RsiV into pDR111; start primer 
CDEP1561 atcaacccggacgcc gct cag tgg atgtcaaagatccct Fwd RsiV site drected AQA/ AQW A66W 
CDEP1562 agggatctttgacatccactgagcggcgtccgggttgat Rev RsiV site drected AQA/ AQW A66W 
CDEP3609 gagcggcgtccgggcagatattaacaagcgcagtg Rev RsiV N60C 
CDEP3610 cactgcgcttgttaatatctgcccggacgccgctc Fwd RsiV N60C  
CDEP3611 gcggcgtccgggttgatacaaacaagcgcagtgaataa Rev RsiV N58C  
CDEP3612 ttattcactgcgcttgtttgtatcaacccggacgccgc Fwd RsiV N58C  
CDEP3613 gcagctattttattcactgcgtgtgttaatatcaacccggacgc Rev RsiV L56C  
CDEP3614 gcgtccgggttgatattaacacacgcagtgaataaaatagctgc Fwd RsiV L56C  
CDEP3623 gacatccactgagcggcgcacgggttgatattaacaag Rev RsiV D62C A66W 
CDEP3624 cttgttaatatcaacccgtgcgccgctcag tgg atgtc Fwd RsiV D62C A66W 
CDEP3764 attttattcactgcgctttgtaatatcaacccggacgcc Rev RsiV V57C  
CDEP3765 ggcgtccgggttgatattacaaagcgcagtgaataaaat Fwd RsiV V57C  
CDEP3766 ttcactgcgcttgttaattgcaacccggacgccgctcag Fwd RsiV I59C  
CDEP3767 ctgagcggcgtccgggttgcaattaacaagcgcagtgaa Rev RsiV I59C  
CDEP3897 gcgcttgttaatatcaactgcgacgccgctcagtggatg Fwd RsiV P61C A66W 
CDEP3898 catccactgagcggcgtcgcagttgatattaacaagcgc Rev RsiV P61C A66W 
RsiV-GFP Fusion    
CDEP3865 aacaattaagcttaaggaggctttcttaatggataagagattacagc PY79 RsiV 5' Clone RsiV-GFP   
CDEP3866 agttcttctcctttgctcattcgaatataacgttctccca PY79 RsiV 3' Clone RsiV-GFP  
CDEP3867 gagaacgttatattcgaatgagcaaaggagaagaact GFP 5' template pCM11   
CDEP3868 ccaccgaattagcttgcatgggatcctttgtagagctcat GFP 3' template pCM11  
CDEP3925 agttcttctcctttgctcatagcctgagcggcgtccgg PY79 RsiV 3' for RsiV(1-66)-GFP  
CDEP3926 ccggacgccgctcaggctatgagcaaaggagaagaact GFP 5' template pCM11 for RsiV(1-66)-GFP  
CDEP3927 agttcttctcctttgctcatgattttgccgatgacagg PY79 RsiV 3' for RsiV(1-76)-GFP  
CDEP3928 cctgtcatcggcaaaatcatgagcaaaggagaagaact GFP 5' template pCM11 for RsiV(1-76)-GFP  
CDEP3929 agttcttctcctttgctcattttgatttcaataaaggt PY79 RsiV 3' for RsiV(1-86)-GFP  
CDEP3930 acctttattgaaatcaaaatgagcaaaggagaagaact GFP 5' template pCM11 for RsiV(1-86)-GFP  
CDEP3931 agttcttctcctttgctcatgacatcaatgcttgattg PY79 RsiV 3' for RsiV(1-96)-GFP  
CDEP3932 caatcaagcattgatgtcatgagcaaaggagaagaact GFP 5' template pCM11 for RsiV(1-96)-GFP  
Cysteine Point Mutations: Into 22 l of dH2O, we put 1 l of B. subtilis PY79 with 6x histidine 
tag and an A66W point mutation for template. We combined Q5 Master Mix, dH2O, B. subtilis 
PY79 with 6x histidine tag and an A66W point mutation template, with forward primer 
CDEP3195 or CDEP3629 in separate PCR tubes in a 1:0.9:0.04:0.04:0.04 fashion, respectively. 
All reactions underwent Q5TD PCR amplification (see above). Using purified DNA bands, we 
conducted Gibson assembly using a pDR111 vector, as previously described [17]. Gibson 
assembly reactions were then transformed into E. coli omnimax and placed into recovery media 
for 1 hour. LB transformation media was then plated onto LB-Amp100 and grown overnight at 
37ºC. Plasmid preps followed by restriction digest with HindIII-HF & SphI checked for presence 
of plasmid insert. After getting desired plasmid construct, we transform it into B. subtilis 
CDE1563 by putting an isolated colony of CDE1563 into 1x MC and was incubated until cells 
were in log phase. We then placed a 1/100 volume of eluted plasmid prep into competent 
CDE1563 and let the mixture incubated for ~1-2 hours before plating onto LB-
Spectinomycin100. Plates were then grown overnight at 37ºC.   
 
Substituted Cysteine Accessibility Mutagenesis (SCAM): We started 5 mL LB liquid media 
ON cultures of strains that expressed a RsiV containing a cysteine residue. Overnights were then 
subculture 1:100 into 50 mL LB liquid media with 1 mM IPTG. Flasks were then grown shaking 
at 37ºC until they reached an OD 600 of ~0.8 (approx. 3 hours). We then pelleted 15 mL of 
culture at 5000 g for 10 min at room temperature. was removed and the cell pellet was 
resuspended in 500 l Protoplast buffer (0.4M Sucrose, 10mM Potassium Phosphate, 15mM 
MgCl2) + MPB (100 g/mL) and left to be biotinylated for 30 minutes. Labeling was quenched 
by adding 5 l -Mercaptoethanol. Cells were pelleted (13,000 xg for 1 minute) and supernatant 
removed before resuspension with 500 l of wash Protoplast + BME (20 mM). Cell were then 
spun down (13,000 x g for 1 minute). Small scale protein purification was performed by lysing 
the cell with 500 l of 3 mM TritonX-100 (TX100) and sonicating. Cell lysates were then spun 
at 15,000 x g for 10 minutes and the clarified lysate was then added to 50 l of HisPur Ni-NTA 
Resin that was washed twice with 500 l 3 mM TX100 lysis buffer (50 mM NaH2PO4, 250 mM 
NaCl, 10 mM imidazole, pH 8.0; spun for 30 seconds at 2,000 x g). The lysate was then rocked 
at 4ºC for 30 minutes before being spun down for 30 seconds at 2,000 x g. The supernatant was 
removed and the resin washed 3 times with 500 l of 0.3 mM TX100 wash buffer (50 mM 
NaH2PO4, 250 mM NaCl, 20 mM imidazole, pH 8.0; spun for 30 seconds at 2,000 x g). Resin-
bound protein was then eluted with 50 l of 0.03 mM TX100 elution buffer (50 mM NaH2PO4, 
250 mM NaCl, 250 mM imidazole, pH 8.0) before being spun at 2,000 x g for 30 seconds. 
Elution buffer was removed and added to 50 l of 2x sample buffer + BME (40 mM). Our 
western blot analysis used 1) 1:10,000 Anti-RsiV primary antibody + 1:10,000 Tween 20 
[Polyoxyethylenesorbitan Monolaurate] (blocked using 5% nonfat dried milk in 1x PBS) with 
anti-rabbit secondary antibody (1:10,000) or 2) Streptavidin IR dye 800 (1:10,000, blocked in 
5% Albumin, Bovine Fraction V (BSA) in 1x PBS, covered) + 1:10,000 Tween 20 
[Polyoxyethylenesorbitan Monolaurate]. The blots were imaged using a LI-COR Odyssey CLx.  
 
RsiV-GFP Fusion Constructs: We amplified the desired portion of RsiV from B. subtilis PY79 
template and GFP from pCM111 template. Gibson assembly and transformation into E. coli 
omnimax or B. subtilis strain PY79 ∆sigVrsiV::kan were done as described above. 
 RsiV-GFP Construct Western Blot Cell Preparation: Cells were grown overnight in 5 mL LB 
at 37ºC. The overnight cultures were diluted 1/100  into 5 mL fresh liquid LB + 1mM ITPG and 
grown shaking to mid log (~3 hours) at 37ºC. 1.5 mL cells were pelleted (13,000g for 2 min) and 
500 l of supernatant was saved from each strain before discarding the rest. Pellets were 
resuspended in 150 l liquid LB. To lyse cells 150 l of 2x sample buffer + BME was added to 
the pellets and samples were sonicated, as described above. The proteins in the supernatant were 
concentrated using a Methanol Chloroform Extraction (see below). Western blot analysis was 
done using Anti-GFP primary antibody (1:2,000; blocked in 5% nonfat dried milk in 1x PBS) 
and Anti-rabbit secondary antibody (1:10,000). The blots were imaged using a LI-COR Odyssey 
CLx.  
 
Methanol-Chloroform Extraction: Proteins in the supernatant were concentrated by mixing 
equal volumes of culture supernatant and MeOH along with ¼ volume of CHCl3 and vortexing 
vigorously. Mixtures were then centrifuged at 15,000g for 5 minutes. The top phase was 
removed without disrupting the interface and discard. 500 l MeOH was added and the samples 
vortexed. Samples were then centrifuged at 15,000g for 2 minutes. Supernatant was removed, 
discarded, and the pellet left to dry before resuspension in 75 l 2x Sample buffer + BME and 
heating at 90°C for 8 minutes to resuspend the pellet.  
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